Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA

Tauber, RL; Feuerecker, B; Knorr, K; Beheshti, A; Seidl, C; D'Alessandria, C; Bruchertseifer, F; Retz, M; Gschwend, JE; Weber, W; Morgenstern, A; Eiber, M

ANNALS OF ONCOLOGY, 2019; 30 ():